IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
mpact of Valsartan on clinical outcome in obese hypertensive patient

Author: MSC. Y, PROF. DR. SAFFA A KHUDAIR, ASST. PROF. DR. HUSSEIN A SAHIB, PROF. DR. BASIM I MUHAMMED, NAJAH R. HADI
Abstract: Obesity and its associated cardiovascular, metabolic and renal disorders have quickly become a major threat to global health. In obese individuals, studies have shown predominant high levels of plasma rennin activity, angiotensinogen, Angiotensin II and aldosterone values. Angiotensin II type 1 receptor blockers constitute an integral part in hypertension management and outcome improvement, however still there is inter-individual variation in response to ARBs which can be attributed to obesity .Therefore, this study aimed to find out the effect of obesity on angiotensin II type 1 receptor responsiveness in hypertensive patient treated with valsartan. Study accomplished by enrolling 96 individuals(males and females) aged between 24-65 years, of Arab ancestry diagnosed with essential hypertension were recruited by the specialist physician of Al-Sader teaching hospital in Najaf governorate and Al-Diwaniyah teaching hospital at Al-Diwaniyah governorate. A mean dose of 110.8mg of valsartan was administered for 3 weeks as a monotherapy, blood pressure was measured before and 3 weeks after treatment. Height, weight, hip circumference, waist circumference, leptin level were measured. The subjects were classified (depending on BMI) into two group, overweight/obese patient (whose BMI=25) 84 patients and normal weight patient 12 patients (whose BMI less than25). The mean Systolic blood pressure at baseline was 173.5417 ±1.75675 and the mean diastolic blood pressure at baseline was 109.7604 ±1.03785. Valsartan (mean dose 110.8 mg) significantly (p value 0.05) reduced the systolic blood pressure to a mean of 139.4271±1.19591 and mean diastolic blood pressure to a mean of 88.6979 ±0.92256.compare to leptin level is higher in over weight\obese than in normal weight(2573.6 in normal weight,4226.7 in overweight\obese with p value 0.0001) can be conclude that valsartan is effective in the treatment of hypertensive obese patients it act by blocking angiotensin II type 1 receptor (involved in pathogenesis of obesity and hypertension). Large sample size, multi center cities and Include large number of normal weight hypertensive patient were required.
Keyword: Valsartan, clinical outcome, hypertensive patient
DOI: https://doi.org/10.31838/ijpr/2020.12.02.0167
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free